

Oncology FORUM

2026 UK Oncology Forum
22nd Annual Conference

Thursday 11th & Friday 12th June 2026

Harrogate Convention Centre

FINAL PROGRAMME

This meeting is for UK Oncology NHS Healthcare Professionals ONLY

The UK Oncology Forum programme has been wholly designed by the UK Oncology Forum Faculty and session chairs. No sponsors have had any input in to the UKOF programme or the choice of speakers and have provided sponsorship monies used towards venue, catering, audiovisual and materials. Sponsoring companies will have the opportunity to have an exhibition stand during the meeting. Please refer to the last page of the programme for the full list of sponsors. The faculty, chairs, and speakers of the UKOF have had no input or influence over Industry symposia. The UK Oncology Forum is ABPI & RCP compliant. CME will NOT be awarded to all industry symposiums. All HCPs must attend the required sessions to qualify for CME certificates of attendance. PATIENTS AND MEMBERS OF THE PUBLIC CANNOT ATTEND, due to ABPI code, compliance, and guidelines. Industry Symposia will NOT be run parallel to the UKOF programme

To receive your certificate of attendance for CPD points:

- You must attend clinical sessions on both days
- You must attend the keynote opening and closing sessions
- The meeting will run strictly to the ABPI code of conduct
- The meeting is open to UK HCPs ONLY

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

DAY ONE – THURSDAY 11TH JUNE 2026

*Additional refreshment breaks in the Exhibition Hall

TIME	SUBJECT			
10:00hrs ~ 11:45hrs	CCA-UK Meeting in partnership with BASL - Harewood 2, Crowne Plaza			
	1000-1005	Welcome and introduction	Mr Hassan Malik	
	1005-1030	Talk 1: Epidemiology/Regional Diffs	Dr Sophie Jose	
	1030-1050	Talk 2: Update on Systemic Rx	Dr Akhila Wimalasingham	
	1050-1115	"Patient and Public Involvement and Engagement in the battle against CCA"		Pre-recorded message from Helen Morement of AMMF
			Talk 3: BSG Guidelines	Mr Hassan Malik
1115-1200	Talk 4: Panel Discussion of 2 or 3 MDT Cases in light of new guidelines		Panel [and AI]	
10:00hrs ~ 11:45hrs	Cancer Alliances network meeting (Invitation Only) - Harewood 1, Crowne Plaza			
10:30hrs ~ 11:30hrs	Astellas Platinum Sponsor - Ripley Suite, Crowne Plaza			
10:30hrs ~ 11:30hrs	Bristol Myers Squibb Platinum Sponsor - Queen Suite 3, HCC			
10:30hrs ~ 11:30hrs	Johnson & Johnson Platinum Sponsor - Queen Suite 5, HCC			
10:30hrs ~ 11:30hrs	AstraZeneca Platinum Sponsor - Hall D, HCC			
11:45hrs ~ 12:45hrs	NOVARTIS DIAMOND SPONSOR SYMPOSIUM – King Suite, HCC			
12:00hrs ~ 12:55hrs	STUDIO ONE - LUNCH & REFRESHMENTS - EXHIBITION HALL PLEASE VISIT THE STANDS)			

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
 Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

DAY ONE – THURSDAY 11TH JUNE 2026 all clinical sessions will run in parallel

*Additional refreshment breaks in the Exhibition Hall

TIME	SUBJECT		
13:00hrs ~ 13:05hrs	UKOF OPENS ~ WELCOME & INTRODUCTION – CHAIR: Professor Ruth Plummer MBE – Main Auditorium, HCC		
13:05hrs ~ 14:00hrs	OPENING KEYNOTE SPEAKER – Main Auditorium, HCC Dr Mireia Crispin, Group Leader, Early Cancer Institute, Group Leader, Associate Professor, Department of Oncology, University of Cambridge Always on call: AI in Oncology		
14:00hrs ~ 14:25hrs	STUDIO ONE REFRESHMENTS - EXHIBITION HALL PLEASE VISIT THE STANDS)		
14:30hrs ~ 17:25hrs	BLADDER BREAKOUT – CO CHAIRS: Professor Peter Hoskin & Professor Ananya Choudhury – Ripley Suite, Crowne Plaza There is increasing interest in the use of checkpoint inhibitors for NMIBC and a comprehensive overview of the data supporting their role will be delivered in our opening lecture. This will be followed by a review of the current standard of care for MIBC and adherence to guidelines in practice with an updated presentation of the RCR audit data. EVP has made a major impact in the field of systemic treatment for MIBC but with increasing use outside clinical trials challenges arise in patient management with toxicity. This will be addressed in our third talk followed by a final presentation on the SORT trial, a further attempt to address the comparison of surgery and radiotherapy in bladder cancer using real world evidence. Capturing current interests in bladder cancer, this session will explore the controversies behind data. We will explore whether there is a compelling case for the use of checkpoint inhibitors in non-muscle invasive bladder cancer. Use of novel treatments including the recent introduction of Enfortumab vedotin and pembroluzimab can be challenging in a real world practice and we will discuss how best to do this. The UK continues to provide insights in the role of bladder preservation with data presented from a reaudit by the Royal College of Radiologists. The debate continues about the comparison of radiotherapy with surgery for radical treatment of bladder cancer and new data from the SORT trial, a real world study using data from NHS England will provide compelling insights. We're looking forward to provocative discussion at OF26.		
	1430-1440	Welcome and introduction	Professor Peter Hoskin & Professor Ananya Choudhury
	1440-1510	Checkpoint inhibitors for NMIBC - boom or bust	Dr Killian Gust
	1510-1540	The RCR bladder audit	Dr Sarah Treece
	1540-1600	Comfort Break	All
	1600-1630	EVP in the clinic and managing toxicity	Dr Hilary Glen
	1630-1700	The SORT trial: can real world data be used to answer impossible trials?	Dr David Lugo Palacios
	1700-1725	Panel Q and A, summary and close	Professor Peter Hoskin & Professor Ananya Choudhury

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
 Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
14:30hrs ~ 17:25hrs	BREAST BREAKOUT – CHAIR: Dr Marina Parton - Kings Suite, HCC		
	The first section of talks will look at oligometastatic disease and radical approaches from the multidisciplinary team either with surgery or radiotherapy on a background of stage IV disease. Who are the most suitable patients, what is the evidence for this approach? In both early and metastatic disease, supporting patients is key to compliance and better outcomes- we home in on oestrogen deprivation and exercise. No hot topic discussion is complete without conference updates—we look at the most topical studies that are relevant to in the clinic in both early and metastatic disease. We end the session with a mock molecular tumour board, where the latest genomic tests and interpretations are translated to treatment in the clinic. Hopefully a highly interactive and relevant session to all involved in breast cancer.		
	1430-14.35	Welcome and introduction	Dr Marina Parton
	1435-1445	Oligometastatic disease – what’s the right balance -the surgeon’s perspective	
	1445-1455	Oligometastatic disease- the Medical Oncologist perspective	Dr Judy King (Medical Oncologist)
	1455-1505	Oligometastatic disease- the Clinical Oncologist perspective	Dr Alison Ranger (Clinical Oncologist)
	1505-1525	Case histories 2x and discussion	All speakers & Sarah Adomah (Breast CNS)
	1525-1540	Long term oestrogen deprivation therapy- managing menopause better	Dr Charlotte Gooding (Menopause Specialist & GP)
	1540-1600	Comfort break	All
	1600-1620	Conference updates- just the basics EBC, MBC	Dr Ciara O'Brien (Medical Oncologist) Dr Mukesh Mukesh (Clinical Oncologist)
	1620-1635	The evidence for exercise in breast cancer	Dr Caroline Wilson (Medical Oncologist)
	1635-1645	Genomics; introduction to Molecular Tumour Boards (MTBs)	Dr Zoe Kemp (Clinical Geneticist & Medical Oncologist)
	1645-1705	MTB panel, case histories and discussion	Judy, Ciara, Zoe, Rachel Rock (Research Nurse), Paula Prosek (Clinical Scientist)
1705-1715	Summary and close	Dr Marina Parton	

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT	
14:30hrs ~ 17:25hrs	COLORECTAL BREAKOUT – CHAIR: Professor Vicky Coyle – Harewood 2, Crowne Plaza	
	Advances in CRC: Emerging data, immunotherapy and real-world decision making	
	Brief:	
	The management of colorectal cancer is evolving rapidly with advances in immunotherapy, precision medicine and treatment sequencing decisions increasingly shaping clinical practice across both early and advanced CRC. This session will provide a practical and evidence-focused update for oncologists involved in the multidisciplinary management of colorectal cancer, combining expert talks and an interactive case-based MDT discussion. The format is intended to encourage practical discussion around treatment decision-making in early stage and advanced CRC including the challenges encountered in implementing these into routine practice.	
	Learning objectives:	
	By the end of this session, participants will be able to:	
	<ul style="list-style-type: none"> • Describe the current and emerging role of immunotherapy in CRC • Evaluate key CRC data presented at recent conferences and assess its relevance to UK clinical practice. • Optimise treatment selection and sequencing in advanced CRC • Discuss practical challenges and MDT considerations in implementing novel therapies in routine care pathways. 	
	1430-1440	Welcome and introduction
1440-1510	Updates from ESMO and ASCO	Professor Jenny Seligmann
1510-1540	Immunotherapy	Dr Kai Keen Shiu
1540-1600	Comfort Break	All
1600-1715	Cases (early-stage CRC and advanced CRC) and discussion	Professor Richard Adams Dr Mark White Professor Jenny Seligmann Dr Susie Slater Professor Naureen Starling Professor Richard Wilson
1715-1725	Summary and close	Professor Vicky Coyle

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
14:30hrs ~ 17:25hrs	HEAD & NECK – CHAIRS: Dr Will Ince & Dr Ben O’Leary - Queen Suite 2, HCC 'Hype versus reality; changing the head and neck paradigm'		
	Head and neck oncology is entering an exciting but uncertain period, with peri-operative immunotherapy, antibody–drug conjugates, bispecifics, ctDNA, radiomics, de-escalation, re-irradiation, robotic surgery and new hope in side effect management all promising more personalised treatment, better outcomes and reduced toxicity. The hype is understandable, but the reality is more complex: many advances are based on selected trial populations, immature survival data, surrogate endpoints, high costs, difficult toxicity profiles and pathways that may not be deliverable in routine UK practice. This session will examine what is genuinely practice-changing now, what remains speculative, and how clinicians should interpret emerging data for patients in clinic, focusing on the gap between trial efficacy and real-world benefit, the limits of PD-L1 and other biomarkers, the safety of de-escalation, and why multidisciplinary buy in is vital. The aim is to separate realistic clinical progress from over-interpretation and leave the audience with a pragmatic view of what should change on Monday morning.		
	1430-1440	Welcome and introduction	Dr Will Ince & Dr Ben O’Leary
	1440-1500	TORS for HNSCC	Dr Somiah Siddiq
	1500-1520	ORN	Dr Sarah Hargreaves
	1520-1540	Comfort Break	All
	1540-1600	Surgical View	Mr David Hamilton
	1600-1620	Salivary Gland Cancer	Professor Paolo Bossi
	1620-1700	All MDT discussion	All
1700-1715	Summary and close	Dr Will Ince & Dr Ben O’Leary	

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
14:30hrs ~ 17:25hrs	LUNG BREAKOUT – CHAIR: Professor Samreen Ahmed - Queen Suite 1, HCC		
	Please join us for the lung cancer session at UKOF 2026. This year we will be reviewing the landscape change in the early-stage NSCLC, with the first author of the pivotal CM816 study Professor Patrick Forde. Then we have practice changing studies presented in the last 12 months at the world congresses. Finishing with the new and sexy drugs that will impact lung cancer in the next few years. This session will bring you up to date and inform you of what to expect in the next few years in both small cell and non-small cell lung cancer.		
	14:30-1435	Welcome and introduction	Professor Samreen Ahmed
	1435-1500	Developments in Early-Stage NSCLC	Professor Patrick Forde
	1500-1530	Practice changing data in SACT 2025/26	Dr Shobhit Baijal
	1530-1600	BITES/TILs/CAR-T explained cellular therapies coming to a centre near you!	Dr Sean Dullo
	1600-1615	Comfort break	All
	1615-1640	Practice changing data in radiotherapy 2025/26	Dr Crispin Hiley
	1640-1700	Application of liquid biopsy	Professor Mike Hubank
	1700-1720	Antibody Drug Conjugates/Bispecific Antibodies: Basics and application in Lung Cancer	Dr Tanya Ahmad
1725	Summary and close	Professor Samreen Ahmed	

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: *Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson*

TIME	SUBJECT		
14:30hrs ~ 17:25hrs	MELANOMA BREAKOUT – CHAIR: Dr Pippa Corrie - Queen Suite 3, HCC		
	<p>The roles of specialist surgeons and oncologists continue to adapt to the rapidly evolving melanoma treatment landscape. This session will address the challenges surgeons face in managing complex locoregional melanoma, particularly as neoadjuvant therapy enters routine practice, and the key role of specialist nurses supporting patients through increasingly complex pathways and decision-making.</p> <p>Now that immunotherapy has become established as standard of care treatment for both advanced and high-risk resected melanoma, the risks and benefits for patients and payers are being scrutinised through large volume real world national datasets. Together, they raise the question, is more always better? New research findings will be shared to better equip clinicians when developing personalised treatment plans for patients with both early and late-stage melanoma.</p>		
	1430-1435	Welcome and introduction	Dr Pippa Corrie
	1435-1500	Management of locoregional melanoma	Professor Rowan Pritchard-Jones
	1500-1520	Incorporating Specialist nurse clinics to enhance skin cancer patient care	Dr Sali Putt
	1520-1540	Panel Discussion: How can we enhance skin cancer patient pathways within modern healthcare constraints?	Panel
	1540-1600	Comfort Break	All
	1600-1630	Impact of adjuvant systemic therapy for resectable melanoma on overall survival	Dr Nicola Thompson
	1630-1700	Early discontinuation of immunotherapy as first line treatment for metastatic melanoma: results of the SAFE-STOP trial	Dr Astrid A M van der Veldt
	1700-1725	Panel Discussion: Are we prescribing too much systemic immunotherapy?	Panel
	1725	Close	Dr Pippa Corrie

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
14:30hrs ~ 17:25hrs	Updates on Malignancy of Unknown Origin (MUO) and Cancer Unknown Primary (CUP) – Co-chairs: Natalie Cook and Sonali Dasgupta Queen Suite 4, HCC		
	<p>This session provides an integrated overview of malignancy of unknown origin (MUO) and cancer of unknown primary (CUP), focusing on contemporary diagnostic pathways, service innovations, and evolving management strategies within the UK and internationally. The programme combines case-based learning, pathway evaluation, and research perspectives to support clinicians managing these complex patient groups.</p> <p>We will highlight real-world case discussions alongside examination of current pathways, including the role of rapid diagnostic centres and streamlined clinic models in improving diagnostic efficiency and patient experience. It also incorporates perspectives on international approaches, emerging research developments, and the importance of embedding patient and carer experiences.</p> <p><u>Learning Objectives</u></p> <p>By the end of this session, participants will be able to:</p> <ul style="list-style-type: none"> • Understand the diagnostic challenges patients with MUO/CUP face. • Utilise appropriate diagnostic and referral pathways for patients presenting with suspected MUO/CUP, incorporating multidisciplinary working. • Understand the role of rapid diagnostic centres and tailored treatment approaches. • Discuss emerging developments and future directions in MUO/CUP care including research advances 		
	1430-1435	Introduction to MUO and CUP	Dr Sonali Dasgupta
	1435-1450	Case Study: MUO	Dr Ben Nelson
	1450-1505	MUO pathways – how can we improve?	Ms Alison Taylor
	1505-1520	The value of Rapid Diagnostic Centres and role in the MUO/CUP pathway	Dr Laura Jones
	1520-1530	Panel Q and A session	All Speakers
	1530-1540	Comfort Break	Dr Sonali Dasgupta
	1540-1555	Case Study: CUP	Dr Adam Sharif
	1555-1615	CUP management in France: a model for the future	Dr Sarah Watson
	1615-1625	The Rotherham one-stop clinic	Dr Vicky Athey
	1625-1630	Q&A	All
	1630-1650	Research updates in CUP	Dr Kai-Keen Shiu
	1650-1705	Patient and carer perspective and the World CUP Alliance	Ms Tanya Knott World CUP Alliance Founder
1705-1720	What does the future look like for MUO/CUP?	Dr Natalie Cook	
1720-1725	Panel Q and A session / Close	All Speakers	

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
14:30hrs ~ 17:25hrs	PANCREATIC BREAKOUT – CO CHAIRS: Professor David Chang & Dr Fieke Froeling - Bramham Suite, Crowne Plaza		
	In this session, four multi-disciplinary experts will discuss advances and challenges in the management of pancreatic cancer, from tissue acquisition, diagnosis and different treatment modalities. Dr Joe Geraghty, Consultant Gastroenterologist, will discuss the advances in endoscopy approaches for tissue acquisition and biliary drainage in patients with pancreatic cancer. Dr Alison Cairns, Consultant Cellular Pathologist, will provide an overview of pancreatic and ampullary cancer pathology, its subtypes as well as molecular pathology. This will be followed by a panel discussion regards the overall diagnostic challenges and approaches in the current era of molecular testing. After a short break, Professor Grainne O’Kane, Consultant Medical Oncologist, will discuss novel therapeutics, including novel KRAS inhibitors and other promising results presented at recent ASCO and other ongoing trials. Dr Ganesh Radhakrishna, Consultant Clinical Oncologists will discuss advances in radiotherapy approaches and whether there is a role for these in pancreatic cancer treatment. This will be followed by a second panel discussion on the treatment of pancreatic cancer now and in the near future and how we can ensure benefits to the UK patients.		
	1430-1435	Welcome and Introduction	Professor David Chang & Dr Fieke Froeling
	1435-1505	Tissue acquisition and biliary drainage in pancreatic cancer	Dr Joe Geraghty
	1505-1530	Pathology of pancreas and ampullary cancers	Dr Alison Cairns
	1530-1550	Panel Discussion: diagnostic challenges in pancreatic cancer, molecular testing and role of AI	Panel Q and A session
	1550-1605	Comfort Break	All
	1605-1635	Therapeutic advances in pancreatic cancer, KRAS inhibitors and beyond	Prof Grainne O’Kane
	1635-1700	Role of radiotherapy in pancreatic cancer	Dr Ganesh Radhakrishna
	1700-1725	Panel Discussion: what will treatment of pancreatic cancer look like in the near future and how to ensure UK pancreatic cancer patients benefit?	Panel Q and A session
1725	Summary and closure	Professor David Chang & Dr Fieke Froeling	

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
14:30hrs ~ 17:25hrs	PROSTATE BREAKOUT – CHAIR: Dr Finbar Slevin - Queen Suite 5, HCC		
	This session will address current hot topics in the diagnosis and management of prostate cancer, using clinical cases and evidence from key recent and ongoing clinical trials to address areas of uncertainty and controversy in practice. We will discuss screening, the management of pelvic lymph nodes in patients undergoing surgery, the role of pelvic nodal radiotherapy in the primary, post-operative and salvage settings and where reirradiation of locally recurrent disease after primary radiation therapy could benefit patients. By the end of the session, participants will be able to:		
	<ul style="list-style-type: none"> • Understand the potential benefits and harms from screening for prostate cancer • Understand where treatment of pelvic nodes should be considered for patients managed with surgery or radiotherapy • Understand the potential role for reirradiation of locally recurrent prostate cancer 		
	1430-1440	Welcome and introduction	Dr Finbar Slevin
	1440-1510	Screening	Mr Jeremy Oates
	1510-1540	PLND in high risk PCa, current state of play in the UK and what are we doing from a research point of view to improve prostate cancer care	Professor Krishna Narahari
	1540-1600	Comfort break	All
	1600-1630	Reirradiation for locally recurrent prostate cancer	Dr Finbar Slevin
1630-1700	The role of pelvic lymph node irradiation for prostate cancer in the primary, post-operative and salvage settings	Professor Isabel Syndikus	
1700-1715	Summary and closure	Dr Finbar Slevin	

*Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson*

TIME	SUBJECT		
14:30hrs ~ 17:25hrs	TREATING THE OLDER CANCER PATIENT BREAKOUT – CHAIR: Professor Kwok-Leung Cheung - Harewood 1, Crowne Plaza		
	The majority of cancers occur in older adults. With the growing ageing population, it is important that we provide optimal care and treatment for these patients. This session will cover a multidisciplinary approach in the clinical management of this problem. In addition to hearing from our overseas expert on trial updates, we will look at how geriatric oncology activities are happening in the UK. The session is designed and run by the UK Country Group of the International Society of Geriatric Oncology.		
	1430–1435	Welcome and introduction	Professor Kwok-Leung Cheung
	1435–1500	Geriatric oncology trials including ASCO/ESMO updates	Dr Filipe Coutinho
	1500–1515	Disease biology in older adults with cancer – Is it different and does it matter?	Dr Mark Baxter
	1515–1530	Panel Q and A session	All
	1530–1545	Comfort Break	All
	1545–1600	Cancer care in older people with frailty – An assessment and management toolkit	Professor Kwok-Leung Cheung
	1600–1700	Application of the toolkit in clinical practice – <ul style="list-style-type: none"> - Frailty overview - Assessment - Medical considerations - Surgical considerations 	Dr Kirsty Colquhoun Dr Vanya Slavova-Boneva Dr Mark Baxter Dr Krishna Moorthy
	1700–1710	Panel Q and A session	All
1710–1715	Summary and closure	Professor Kwok-Leung Cheung	

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT
17:30hrs ~ 17:45hrs	Novartis DIAMOND Sponsor Product Talk - Kings Suite, HCC From congress to clinic: risk of recurrence outcomes and KISQALI® (ribociclib) + NSAI NATALEE QoL Dr Mukesh Mukesh, Consultant Clinical Oncologist, East Suffolk and North Essex NHS Foundation Trust
17:30hrs ~ 18:30hrs	Regeneron Platinum Symposium - Queen Suite 1, HCC
17:30hrs ~ 18:30hrs	Takeda Platinum Symposium - Harewood 2, Crowne Plaza
17:30hrs ~ 18:30hrs	Studio One - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS) HOTSPOT SESSIONS – Please see below
19:30hrs ~ 20:00hrs	Pre-dinner drinks Royal Hall, HCC Card Payments Only - please be aware Harrogate Convention Centre now accepts Card & Contactless payments only
20:00hrs ~ 22:00hrs	Complimentary conference dinner, Royal Hall, Harrogate Convention Centre (please note no drinks, bar for wine and spirits – card payments only). Pre-booking ONLY -NO SHOWs will be charged

DAY TWO – FRIDAY 12TH JUNE 2026

*Additional refreshment breaks in the Exhibition Hall

Agenda for each session – all clinical sessions will run in parallel

TIME	SUBJECT
08:00hrs ~ 08:45hrs	Menarini Stemline UK Ltd Gold Symposium - Kings Suite, HCC
08:00hrs ~ 08:45hrs	Pfizer Gold Symposium - Queen Suite 5, HCC
08:00hrs ~ 08:45hrs	Accord Gold Symposium - Queen Suite 1, HCC

*Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson*

TIME	SUBJECT	
09:00hrs ~ 11:55hrs	ACUTE ONCOLOGY - CO CHAIRS: Dr Anthony Cunliffe - Kings Suite, HCC	
	The future of Acute Oncology - what can be delivered outside of the acute setting and what is needed to make this effective and safe. With the 10 Year Health Plan and National Cancer Plan for England outlining a planned shift from acute to community and a similar focus in the Devolved Nations, how can care for the acutely unwell cancer patient be delivered outside the walls of the hospital?	
0900-0915	Welcome and introductions	Dr Anthony Cunliffe
0915-0930	Overview of the 10yr health plan and the England National Cancer plan regarding the shift from delivering care from the acute setting to the community and alignment with plans in the devolved Nations situations	Dr Anthony Cunliffe
0930-1000	Community Oncology Care – what might this look like? In particular what elements of Acute Oncology can be effectively and safely delivered outside of the acute setting	Ms Teresa Corbett and Ms Katie Hudson – AO Transformation Lead, Wessex Cancer Alliance
1000-1030	Urgent Community response – how can we ensure safe and effective management of the acutely unwell cancer patient whilst ensuring care closer to home?	Dr Ella Jackson and Dr Sophie Mitchinson – Barts NHS Trust
1030-1040	Studio One - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
1040-1110	Supporting older people with cancer in the community – how can we work with elderly medicine services to provide optimal care for older people with cancer who become unwell while prioritising keeping them out of hospital?	Dr Juliette Lewis Jones – Consultant Onco-geriatrician, Cardiff and Vale UHB
1110-1140	Immunotherapy Toxicities – with newer treatments being regularly approved, bringing with them new and more complex toxicities, how can integration of services support safe management in the community where possible	Professor Anna Olsson-Brown
1140-1155	What are the workforce needs to deliver this shift? – a discussion regarding workforce changes and educational needs to ensure optimal support for the acutely unwell cancer patient in the community?	Facilitate by the chair
1155	Summary & close	Dr Anthony Cunliffe

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
09:00hrs ~ 11:55hrs	CANCER VACCINES – CHAIR Professor Lennard Lee - Queen Suite 5, HCC		
	<p>Synopsis: The Third Cancer Vaccine Summit is the annual meeting of the UK National Cancer Vaccine Advance, bringing together researchers, clinicians, industry leaders, policymakers, patients and partners to accelerate the development and delivery of cancer vaccines. The Summit supports the national ambition of enrolling 10,000 patients into cancer vaccine clinical trials and aligns with the UK Government’s 10 Year Cancer Plan and Life Sciences Strategy, helping position the United Kingdom as a global leader in cancer vaccine research and innovation.</p> <p>Objective: The meeting aims to advance understanding of cancer immunology, therapeutic vaccination, immunotherapy, clinical trials and translational medicine. Delegates will learn from national flagship programmes, explore emerging scientific and technological advances, share best practice, and build collaborations that can deliver meaningful benefits for patients across multiple cancer types while contributing to a global advance in cancer treatment.</p>		
	0900-0910	Welcome and introduction	Professor Lennard Lee
	0910-0940	UK cancer vaccine AI Scientist and Supercomputing project	Dr Gareth Bloomfield
	0940-1010	NHS England Cancer vaccine launchpad - what it does	Dr Jessica Curtis
	1010-1040	The Global cancer vaccine advance & making vaccines for Brazil and Mexico	Dr Isabela Pedroza-Pacheco
	1040-1100	Studio One - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1100-1130	The Bowel babe cancer vaccine- taking the first step for Wales technology leadership	Professor Andrew Godkin
	1130-1145	Panel Q and A session	All
1145-1150	Summary & close	Professor Lennard Lee	

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
0900hrs ~ 11:55hrs	CLINICAL NURSE SESSION (UKONS) – CHAIR: Dr Mary Tanay - Queen Suite 1, HCC		
	<p>The first half of the UKONS session considers how the Cancer Plan for England may impact the nursing workforce, considering similar plans for Scotland, Wales and Northern Ireland. There is a focus on specific roles, including Clinical Nurse Specialists, Advanced Practitioners and Consultants. During the session we will debate the boundaries of roles and how they contribute to the multidisciplinary team to provide safe and effective care for patients.</p> <p>The second half of the session presents the UKOMIC guideline for oral care in cancer. This will be followed by a focussed session on the causes, prevention and treatment of osteonecrosis of the jaw.</p>		
	0900 – 1045	Cancer plan for England: Implications for the nursing workforce	Dr Mary Tanay
	0900 - 0905	Welcome and Introduction	Dr Mary Tanay
	0905 - 0925	Clinical Nurse Specialists	Miss Linda Sherwood
	0925 - 0945	Advanced Practice Roles	Dr Lauren Dollive
	0945 - 1005	Consultant Roles	Dr Jo Bird
	1005 – 1030	Panel Q and A session	All
	1030 - 1050	Studio One - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1050 – 1110	UKOMIC	Dr Mary Tanay
	1110 – 1120	The New Edition of the UKOMIC - Guidance on Oral Care in Cancer	Joanna Gemmill
	1120 – 1140	Osteonecrosis of the Jaw, Causes, Prevention and Treatment	Dr Charles Kelly
	1140 – 1145	Questions and closing remarks	Dr Mary Tanay

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
09:00hrs ~ 11:55hrs	GYNAECOLOGY BREAKOUT – CHAIR: Dr John McGrane - Queen Suite 4, HCC		
	Gynaecological cancer management is changing at a faster rate than ever before. We have changes in staging, radiotherapy delivery and drug therapies. We have new antibody drug conjugate indications in several gynae sites and multiple more on the horizon. Supporting patients through these new complex treatment pathways is a challenge for all clinicians. In this session we will explore new breakthroughs in gynaecological cancers using relatable real life examples to frame the discussion. Objectives Understand the rapidly changing landscape in gynaecological cancers Discuss new treatments in cervical, endometrial and ovarian cancers Understand and discuss complex cases and patient survivorship		
	0900-0905	Welcome & introduction	Dr John McGrane
	0905-0925	Cervical cancer updates	Dr Gemma Eminowicz
	0925-0945	The role of SABR in gynae cancer	Dr Gemma Eminowicz
	0945-0955	Q&A	All
	0955-1035	MDT cases <ul style="list-style-type: none"> • Endometrial • Vulva • Ovarian • Cervix 	Dr Leonie Eastlake Dr Juliette Anderson Dr Karim El-Shakankery
	1035-1045	Studio One - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1045-1110	Platinum resistant ovarian cancer – beyond Chemotherapy – where are we now?	Dr Lindsay Hennah
	1110-1130	Managing late effects of pelvic radiation disease	Dr Juliette Anderson
	1130-1140	Q&A	All
	1140-1155	Reflections and close	Dr John McGrane

*Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson*

TIME	SUBJECT		
09:00hrs ~ 11:55hrs	IMMUNOTHERAPY BREAKOUT – CHAIR: Professor Benjamin Fairfax – Hall D, HCC		
	<p>“Although immune checkpoint blockade is now central to modern oncology, clinical responses vary substantially between tumour types and across sites of metastatic disease. Even in immunotherapy-sensitive cancers, such as melanoma, the anatomical site of metastasis may influence treatment sensitivity, patterns of response and clinical outcome. Tumour-infiltrating lymphocyte therapy is also entering wider clinical use, although approaches to patient selection, treatment protocols and our scientific understanding of the cellular mediators of benefit continue to evolve. More broadly, cell-based therapies offer considerable therapeutic potential across cancer types, but clinical experience remains concentrated within specialist centres and the field is advancing rapidly.</p> <p>This session will examine how metastatic site influences response to checkpoint immunotherapy, with focused discussions on liver metastases and experimental immunotherapy, and on brain metastases and clinical experience with checkpoint blockade. It will also provide updates on TIL therapy from Basel and expert perspectives on cell-based therapies from The Royal Marsden.</p> <p>Attendees will gain a practical and current understanding of key developments in cancer immunotherapy, including site-specific determinants of response, emerging TIL strategies and the evolving role of cell-based therapies in oncology.”</p>		
	0900-0910	Welcome & introduction	Professor Benjamin Fairfax
	0910-0940	Insights into the link between liver metastases and systemic resistance to cancer immunotherapy	Dr Becki Lee
	0940-1010	Approaches to manage brain metastases in the context of cancer immunotherapy	Dr Miranda Payne
	1010-1030	Studio One - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1030-1100	Which TILs are helpful in immunotherapy? Distinguishing the go getters from the hangers on	Dr David König
	1100-1130	Cell Therapy	Dr Andrew Furness
	1130-1145	Panel Q and A session	All
	1145-1155	Summary & close	Professor Benjamin Fairfax

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
09:00hrs ~ 11:55hrs	LIVER CANCER BREAKOUT – CHAIR: Mr Hasan Malik - Bramham Suite, Crowne Plaza		
	This session will cover the management of Hepato-cellular carcinoma. Speakers will update the audience regarding the burden of disease, management of HCC including loco-regional, surgical, including transplantation and systemic anti-cancer therapies. The session will include interactive case-based discussion and an MDT scenario from experts within the field.		
	0900-0910	Welcome & introduction	Mr Hasan Malik
	0910-0940	Can we optimize patients with liver disease and HCC for liver	Dr Tim Cross
	0940-1010	Interventional Oncology for HCCs in 2026	Dr Peter Littler
	1010-1030	Studio One - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1030-1100	ASCO Highlights and insights on HCC	Dr Alexa Childs
	1100-1130	Liver resection and transplantation for HCC	Ms Barbara Fiore
	1130-1145	Panel Q and A session	All
	1145-1155	Summary & close	Mr Hasan Malik

*Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson*

TIME	SUBJECT		
09:00hrs ~ 11:55hrs	AI IN ONCOLOGY – CHAIR: Harriet Unsworth - Queen Suite 2, HCC		
	<p>Overview: In this session we will discuss the challenges and opportunities of AI in oncology. Dr Amit Samani will share insight from his career path as an NHS Clinical AI Fellow before moving into industry, and how he is bringing this learning back to the clinical setting. Dr Danilo Silva de Carvalho will present on the development of the A-EYE tool, which uses AI to detect and classify retinal toxicities in cancer patients. Dr Paul O'Regan will present his work on using AI for clinical trial matching and how this has been used in the TARGET National study. Dr Frances Pearl will discuss her research to use AI for cancer drug discovery. And finally, Victoria Hellon will preview Cancer Research UK's new Data Science in Cancer Research Strategy, which will be formally launched in late June 2026.</p> <p>Objectives: By the end of this session, attendees will have an improved understanding of the complexities around AI transformation in cancer care, and the multi-disciplinarity that is required for safe and effective AI development and implementation.</p>		
	0900-0925	AI in the NHS and cancer care	Dr Harriet Unsworth
	0925-0945	Clinical perspectives on AI for cancer	Dr Amit Samani
	0945-1005	A-EYE: AI detection of retinal toxicities	Dr Danilo Silva de Carvalho
	1005-1015	Panel Q and A session	All
	1015-1030	Studio One - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1030-1050	Clinical trial matching with AI	Dr Paul O'Regan
	1050-1110	Developing AI tools for biomarker, diagnostics and precision medicine identification.	Dr Frances Pearl
	1115-1130	CRUK's Data Science in Cancer Research Strategy	Ms Victoria Hellon
	1130-1145	Panel Q and A session	All
1145-1150	Summary & close	Dr Harriet Unsworth	

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
09:00hrs ~ 11:55hrs	RADIOTHERAPY BREAKOUT – CHAIR: Dr Rebecca Muirhead - Harewood 2, Crowne Plaza		
	Hypofractionated radiotherapy is becoming standard of care for an increasing number of tumour types within radiotherapy. We aim to discuss its use in three relevant tumour types. Dr Ragu Ratnakumaran completed a PhD in prostate cancer in the Institute of Cancer Research with the team that led and continue to lead the series of trials investigating the use of SABR in prostate cancer. SABR is now being investigated in an increasing range of stages and with an ever-reducing number of fractions. Dr Ratnakumaran will discuss completed trials, ongoing trials and personal perspectives on working in a world leading trials team. Dr Carmel Anandadas is a member of the FAST-Forward Boost team. She will discuss the literature base for 5-fraction breast radiotherapy and discuss which patients should and should not be considered for hypofractionated treatment. Finally, Dr Rebecca Muirhead and Dr Sean O’Cathail will debate whether Short-Course Radiotherapy with chemotherapy or Long-Course radiotherapy with chemotherapy should be standard of care in locally advanced rectal cancer. Within the light-hearted nature of a debate, it will discuss relevant evidence for both strategies and highlight valid reasons for variation and where both strategies may be appropriate.		
	0900-0910	Welcome & introduction	Dr Rebecca Muirhead
	0910-0940	Prostate SABR fractions – how long can we go?	Dr Ragu Ratnakumaran
	0940-1010	Is 5 fraction radiotherapy now standard of care in breast cancer	Dr Carmel Anandadas
	1010-1030	Studio One - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1030-1115	LGI cancer debate – Is SCRT or LCRT preferable when aiming for organ preservation in localised rectal cancer.	Dr Rebecca Muirehead vs Dr Sean O’Cathail
	1115-1145	Panel Q and A session	All
1145-1150	Summary & close	Dr Rebecca Muirhead	

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
09:00hrs ~ 11:55hrs	RENAL BREAKOUT – CHAIR: Dr Lisa Pickering – Harewood 1, Crowne Plaza		
	Synopsis An expert panel will outline the state-of-the-art oncologic treatment of renal carcinoma, incorporating current challenges and the latest data. The session will cover the role of systemic therapy and radiotherapy in localised and metastatic disease, illustrated with MDT-style case-based discussions.		
	Objectives		
	<ol style="list-style-type: none"> 1. Understand when to recommend consideration of adjuvant systemic therapy for resected renal cancer. 2. Feel confident in selecting systemic therapy for treatment of advanced renal carcinoma at initial presentation and after progression. 3. Improve awareness of the evolving role of irradiation in renal cancer management. 		
	0900-0905	Welcome and Introduction	Dr Lisa Pickering
	0905-0925	An update on adjuvant therapy in renal cancer with the new data from 2025/26	Dr Praveena Idaikkadar
	0925-0945	First line systemic treatment of advanced renal cancer. How to choose?	Dr Simon Grummet
	0945-1005	Treatment in second line and beyond - what are options and what is new?	Dr Naveen Vasudev
	1005-1025	When to consider metastasis directed therapy: radiotherapy including SBRT, ablation or surgery.	Dr Will Ince
	1025-1045	Q&A	All Panel
1045-1115	Studio One - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All	
1115-1145	Interactive MDT cases. All panel led by	Dr Lisa Pickering	
1145-1155	Summary & close	Dr Lisa Pickering	

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT	
09:00hrs ~ 11:55hrs	SUPPORTIVE CARE CHAIR: – Dr Dan Monnery Queen Suite 3, HCC	
	<p>The aim of this session is to provide professionals working in oncology with tips and tools to optimise the holistic care of patients alongside their treatment, including management of toxicities, wellbeing advice and interventions and introduction of palliative care. Through examining the breadth of supportive care in this session, professionals should be able to:</p> <ul style="list-style-type: none"> • Describe the initial investigation and management of immunotherapy toxicities and discuss the mechanisms underlying these toxicities • Describe the optimal nutrition advice which we can all provide to patients receiving anticancer treatment, and the criteria for involvement of more specialist services • Discuss the role of exercise in improving cancer outcomes and treatment tolerability, including tips for professionals of how to introduce exercise as a therapeutic intervention • Describe the psychological impacts of cancer and its treatment and review the resources and services available to support patients, as well as how to recognise patients who are struggling psychologically. • Reflect on the ways in which early palliative care can support patients with treatable but not curable cancer and describe changes in medication prescribing, including opioids, which may be safer in those with chronic cancer. 	
	0900-0905	Welcome and Introduction Dr Dan Monnery
	0905-0930	Toxicity Management Professor Anna Olsson Brown
	0930-0955	Nutritional Optimisation Lucy Eldridge
	0955-1020	Exercise Advice and Support through Cancer Treatment Professor Helen Jones
	1020-1045	Studio One- Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS) All
	1045-1110	Psychological Health in Cancer Dr Robin Muir
	1110-1135	Early Palliative Care Dr Dan Monnery
	1135-1150	Q&A Panel All
	1150-1155	Summary and Close Dr Dan Monnery

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT		
09:00hrs ~ 11:55hrs	UPPER GI BREAKOUT – CO CHAIRS: Professor Russell Petty & Professor Janet Graham – Ripley Suite, Crowne Plaza		
	In this session we will look at what the latest clinical trial results mean for the practice of gastroesophageal oncology, particularly focusing on how to achieve the optimal use of new treatments in individual patients. The emerging concept of oligometastatic gastroesophageal cancer will be discussed and current clinical trial approaches to define and understand this more precisely. There will also be an opportunity to hear about latest data presented at ASCO. Audience members will have the opportunity to interact with speakers in question-and-answer panels.		
	0900-0905	Welcome and Introduction	Professor Russell Petty & Professor Janet Graham
	0905-0920	Oesophageal Squamous cell carcinoma: What's new?	Professor Russell Petty
	0920-0950	Oligometastatic disease does it exist and how should we treat it?	Dr Jessie Elliott
	0950-1000	Panel Q and A session	Panel
	1000-1030	Studio One - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1030-1050	Upper GI Update from ASCO 2026	Professor Janet Graham
	1050-1125	Pushing the boundaries in the treatment of Oesophagogastric Cancer	Professor Filippo Pietrantonio
	1125-1140	Panel Q and A session	Panel
1140-1155	Summary & close	Professor Russell Petty & Professor Janet Graham	
12:00hrs ~ 1300hrs	<p>CLOSING KEYNOTE SPEAKER - Main Auditorium, HCC Professor Richard Sullivan FRCS PhD FFPM(Hon), Director, Institute of Cancer Policy and Co-Director of the Centre for Conflict & Health Research King's College London</p> <p>The Future of Global Cancer Care in a Conflicted World</p>		
13:00hrs ~ 14:00hrs	STUDIO ONE LUNCH & REFRESHMENTS - EXHIBITION HALL PLEASE VISIT THE STANDS)		

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
 Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

TIME	SUBJECT
13:15hrs ~ 14:00hrs	Caris Life Gold Symposium - Harewood 2, Crowne Plaza
13:30hrs	SIOG – Queen Suite 3, HCC
13:45hrs	<p>DSU CRUK Meeting Open – Harewood 1, Crowne Plaza</p> <p>An introduction to the CRUK Data Science Community</p> <p>The CRUK Data Science Community is a newly rebranded, rapidly expanding national network designed to connect clinicians, researchers, data scientists, and technical specialists who are driving data-enabled cancer research across the UK. Its purpose is to create a vibrant, inclusive environment where clinical expertise and data science innovation come together supporting the translation of real-world data, AI tools, biobanking, spatial biology, and health-system intelligence into meaningful improvements for patient care. Structured around thematic Data Interest Groups, the community provides a central hub for sharing best practice, surfacing challenges, co-developing methods, and shaping future capability. For clinicians, it offers an accessible entry point into emerging data-driven approaches, opportunities to influence methodological priorities, and a space to collaborate directly with data specialists. This workshop will introduce the community’s vision, showcase its relevance to clinical practice, and explore how clinicians can actively shape the next phase of UK cancer data science.</p>
13:45hrs	UK Society for Medical Oncology Meeting Invitation ONLY – Ripley Suite, Crowne Plaza
13:45hrs	BCOG Invitation ONLY - Bramham Suite, Crowne Plaza
14:00hrs	CUP UK Group Meeting – All welcome - Queen Suite 1, HCC
13:45hrs	NOTCH AGM Open - Queen Suite 5, HCC
14:00hrs	Women for Oncology UK – Queen Suite 4, HCC

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: *Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson*

New Look Exhibition Hotspots

Join us in the Hall and be part of these engaging and interactive sessions

Thursday 11th June 2026

Time	Hotspots
12:10hrs ~ 12:25hrs	Women for Oncology UK Overview Mona Hassan, SPR Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust
12:30hrs ~ 12:45hrs	Platinum Sponsor - BeOne Medicines UK, Ltd Five top tips on clinical research and publications Professor Samreen Ahmed
17:30hrs ~ 17:40hrs	BOPA – John Leggett
17:40hrs ~ 18:10hrs	Live Immunobuddies Podcast all welcome

New Look Exhibition Hotspots

Join us in the Hall and be part of these engaging and interactive sessions

Friday 12th June 2026

Time	Hotspots
10:45hrs ~ 10:55hrs	BOPA - John Leggett
11:00hrs ~ 11:15hrs	UKOMiC – Joss Harding, Dental Hygienist
13:05hrs ~ 13:20hrs	Platinum Sponsor - BeOne Medicines UK, Ltd Older adults in clinical trials – present challenges and future solutions Dr Mark Baxter
13:25hrs ~ 13:45hrs	Cancer and sexuality , <i>A brave and unembarrassed look at sexuality and cancer</i> Dr Thitikorn Nuamek, Jac Livsey Fellow in Health Inequalities

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson

Secretariat



Athena Medical PR Limited (trading as Athena Meetings & Events)

2 Kingdom Street, 6th Floor, London, Greater London, W2 6BD, UK

Company number **03452033**

Website: www.oncologyforum.co.uk

Direct Line: +44 (0) 1625 619450

Contact Details

Sharon Poole sharon@athenameetings.com

Lisa Young lisa@athenameetings.com

*Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson*

www.oncology-forum.co.uk/

UK ONCOLOGY FORUM 2026 SPONSORS

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting.

 <p>DIAMOND SPONSOR</p>	
 <p>PLATINUM SPONSOR</p>	
 <p>GOLD SPONSOR</p>	

Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson



MERCK



IMMUNOCORE

SERVIER



DATAR
CANCER GENETICS



Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards event delivery, venue, catering, audiovisual. Sponsors will have the opportunity to exhibit during the meeting
Faculty: Professor Ruth Plummer MBE (Chair), Professor Daniel Hochhauser (Vice Chair), Professor Richard Adams, Professor Sarah Blagden, Dr Martin Eatock, Professor Fiona Thistlethwaite & Professor Richard Wilson